Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
D000818:Animals; D000911:Antibodies, Monoclonal; D002292:Carcinoma, Renal Cell / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007553:Isotope Labeling; D007680:Kidney Neoplasms / Q000532:radiotherapy*; D008187:Lutetium; D051379:Mice; D008819:Mice, Nude; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000627:therapeutic use; D012211:Rhenium; D014018:Tissue Distribution; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D011868:Radioisotopes; D015021:Yttrium Radioisotopes; C054343:1-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid; D008187:Lutetium; D012211:Rhenium; D004369:Pentetic Acid